Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Non-Current Deffered Revenue (2019 - 2025)

Legend Biotech filings provide 7 years of Non-Current Deffered Revenue readings, the most recent being -$277000.0 for Q2 2025.

  • On a quarterly basis, Non-Current Deffered Revenue rose 5.46% to -$277000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was -$277000.0, a 5.46% increase, with the full-year FY2023 number at $48.0 million, changed N/A from a year prior.
  • Non-Current Deffered Revenue hit -$277000.0 in Q2 2025 for Legend Biotech, down from -$134000.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $48.0 million in Q4 2023 to a low of -$484000.0 in Q3 2023.
  • Median Non-Current Deffered Revenue over the past 5 years was -$188000.0 (2021), compared with a mean of $2.8 million.
  • Biggest five-year swings in Non-Current Deffered Revenue: crashed 158.77% in 2021 and later increased 18.61% in 2024.
  • Legend Biotech's Non-Current Deffered Revenue stood at -$295000.0 in 2021, then grew by 20.68% to -$234000.0 in 2022, then skyrocketed by 20596.58% to $48.0 million in 2023, then plummeted by 100.9% to -$430000.0 in 2024, then skyrocketed by 35.58% to -$277000.0 in 2025.
  • The last three reported values for Non-Current Deffered Revenue were -$277000.0 (Q2 2025), -$134000.0 (Q1 2025), and -$430000.0 (Q3 2024) per Business Quant data.